Download full-text PDF |
Source |
---|
Cell Transplant
January 2025
Department of Hematology, 920th Hospital of Joint Logistics Support Force, Kunming, China.
Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. Effective interventions to reduce DSAs are still needed, and the cost of the current therapies is relatively high.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Importance: Nelonemdaz selectively antagonizes the 2B subunit of the N-methyl-d-aspartate glutamate receptor and scavenges free radical species.
Objective: To evaluate whether nelonemdaz enhances the clinical outcomes of patients with acute ischemic stroke undergoing emergent reperfusion therapy.
Design, Setting, And Participants: This multicenter double-blind placebo-controlled randomized phase 3 trial (December 25, 2021, to June 30, 2023, in South Korea) recruited patients with acute ischemic stroke who met the following criteria: National Institutes of Health Stroke Scale score greater than or equal to 8, Alberta Stroke Program Early Computed Tomography score greater than or equal to 4, and endovascular thrombectomy within 12 hours after stroke onset.
Future Cardiol
January 2025
Echocardiography research Center, Rajaie cardiovascular medical and research Center, Iran University of Medical Science, Tehran, Iran.
Introduction: Decreased left atrial appendage emptying velocity (LAAV) is a marker for thrombus formation. This study evaluates the association between LAAV and inflammatory indices in non-valvular atrial fibrillation (AF) patients.
Methods: The study population was 1428 patients with AF, 875 of whom enrolled.
Asian Pac J Cancer Prev
January 2025
Center Incharge, Sultan Qaboos Comprehensive Cancer Care and Research Centre (SQCCCRC), University Medical City, Muscat, Oman.
Purpose: This project aimed to minimize medication errors and improve safe medication administration in an oncology setting in Muscat, Oman.
Methods: The study, spanning from the second quarter of 2022 to the first quarter of 2023, employed a one-group pretest-posttest quasi-experimental design, assessing key performance indicators (medication error and medication administration errors rates per 1000 patient days) on quarterly basis before and after implementing targeted interventions. Interventions focused on medication management processes and Healthcare Informatics System (HIS), Environment and equipment, and Education The project utilized the FOCUS PDCA (find, organize, clarify, understand, select, plan, do, check and act) methodology.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!